CN109260152A - A kind of lomefloxacin hydrochloride auristilla - Google Patents
A kind of lomefloxacin hydrochloride auristilla Download PDFInfo
- Publication number
- CN109260152A CN109260152A CN201811344857.XA CN201811344857A CN109260152A CN 109260152 A CN109260152 A CN 109260152A CN 201811344857 A CN201811344857 A CN 201811344857A CN 109260152 A CN109260152 A CN 109260152A
- Authority
- CN
- China
- Prior art keywords
- auristilla
- lomefloxacin hydrochloride
- rilanit special
- glycerol
- ethylene diamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 title claims abstract description 53
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 78
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims abstract description 27
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 27
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims abstract description 27
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000004090 dissolution Methods 0.000 claims description 11
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 229960002422 lomefloxacin Drugs 0.000 claims 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims 1
- -1 rilanit special Substances 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000002776 aggregation Effects 0.000 abstract description 2
- 238000004220 aggregation Methods 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000000149 penetrating effect Effects 0.000 abstract description 2
- 239000004576 sand Substances 0.000 description 12
- 239000012528 membrane Substances 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 206010033078 Otitis media Diseases 0.000 description 3
- 210000000959 ear middle Anatomy 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061926 Purulence Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960002588 cefradine Drugs 0.000 description 2
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003454 tympanic membrane Anatomy 0.000 description 2
- 206010008642 Cholesteatoma Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011903 Deafness traumatic Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 2.5-3.5g, glycerol 40-80g, rilanit special 12-18g, polyethylene glycol 15-25g, disodium ethylene diamine tetraacetate 0.6-1.4g.Lomefloxacin hydrochloride auristilla provided by the invention, using rilanit special and polyethylene glycol as cosolvent, using glycerol as penetrating agent, using disodium ethylene diamine tetraacetate as buffer, lomefloxacin hydrochloride auristilla self aggregation can be made to form micellar solution, both reduced the irritation of auristilla, reduce patient's sense of discomfort, the residence time in ear is extended again, improves bioavailability, obtains better therapeutic effect.
Description
Technical field
The present invention relates to a kind of auristillas, and in particular to a kind of lomefloxacin hydrochloride auristilla.
Background technique
Otitis media purulenta chronica is the common multiple disease of ear-nose-throat department, and according to case and clinical manifestation, this disease is divided into list
Pure type, caries type and cholesteatoma type, wherein it is most commonly seen with simple form, simple form otitis media purulenta chronica is generally used
Conservative treatment is to control infection, adequate drainage.Applicant was once dripped with oral Cefradine Capsules and using lomefloxacin hydrochloride
Ear fluid drug combination achieves good curative effect.But the lomefloxacin hydrochloride auristilla used is using ethyl alcohol as cosolvent, it is right
Ear room mucous membrane has stronger irritation effect, and disease in great pain occurs after having patient feedback that lomefloxacin hydrochloride is added dropwise more
Shape, and medical fluid viscosity is low, is lost seriously, bioavailability is poor.
Summary of the invention
The object of the invention is that providing a kind of lomefloxacin hydrochloride auristilla to solve the deficiencies in the prior art.
The purpose of the present invention is what is realized with following technical proposals:
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 2.5-3.5g, glycerol 40-
80g, rilanit special 12-18g, polyethylene glycol 15-25g, disodium ethylene diamine tetraacetate 0.6-1.4g.
Preferably, contain in every 1000mL auristilla: lomefloxacin hydrochloride 3g, glycerol 60g, rilanit special 15g, poly- second
Glycol 20g, disodium ethylene diamine tetraacetate 1g.
The rilanit special is peg40 rilanit special.
The polyethylene glycol is polyethylene glycol 400.
The preparation method of lomefloxacin hydrochloride auristilla as described above, comprising the following steps: by the hydrochloric acid Lip river of formula ratio
U.S. sand star is added in suitable quantity of water, is heated to 40-50 DEG C, ultrasonic dissolution；Then the glycerol of formula ratio is added, rilanit special, gathers
Ethylene glycol and disodium ethylene diamine tetraacetate, stir evenly, and add water to 1000mL, filter through sterilised membrane filter to get hydrochloric acid Lome sand
Star auristilla.
Lomefloxacin hydrochloride auristilla provided by the invention, using rilanit special and polyethylene glycol as cosolvent, with sweet
Oil is used as penetrating agent, using disodium ethylene diamine tetraacetate as buffer, lomefloxacin hydrochloride auristilla self aggregation can be made to form glue
Beam solution had both reduced the irritation of auristilla, reduces patient's sense of discomfort, and extend the residence time in ear, improves
Bioavailability obtains better therapeutic effect.
Specific embodiment
Embodiment 1
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 2.5-3.5g, glycerol 40-
80g, rilanit special 12-18g, polyethylene glycol 15-25g, disodium ethylene diamine tetraacetate 0.6-1.4g；Rilanit special is preferably
Peg40 rilanit special, polyethylene glycol are preferably polyethylene glycol 400.
The preparation method of lomefloxacin hydrochloride auristilla as described above, comprising the following steps: by the hydrochloric acid Lip river of formula ratio
U.S. sand star is added in suitable quantity of water, is heated to 40-50 DEG C, ultrasonic dissolution；Then the glycerol of formula ratio is added, rilanit special, gathers
Ethylene glycol and disodium ethylene diamine tetraacetate, stir evenly, and add water to 1000mL, filter through sterilised membrane filter to get hydrochloric acid Lome sand
Star auristilla.
Embodiment 2
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 3g, glycerol 60g, peg40
Rilanit special 15g, polyethylene glycol 400 20g, disodium ethylene diamine tetraacetate 1g.
The preparation method of lomefloxacin hydrochloride auristilla as described above, comprising the following steps: by the hydrochloric acid Lip river of formula ratio
U.S. sand star is added in suitable quantity of water, is heated to 45 DEG C, ultrasonic dissolution；Then glycerol, the rilanit special, poly- second two of formula ratio is added
Pure and mild disodium ethylene diamine tetraacetate, stirs evenly, and adds water to 1000mL, filters through 0.45um sterilised membrane filter to get hydrochloric acid Lome
Husky star auristilla.
Embodiment 3
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 3.5g, glycerol 70g,
Peg40 rilanit special 15g, polyethylene glycol 400 23g, disodium ethylene diamine tetraacetate 0.8g.
The preparation method of lomefloxacin hydrochloride auristilla as described above, comprising the following steps: by the hydrochloric acid Lip river of formula ratio
U.S. sand star is added in suitable quantity of water, is heated to 48 DEG C, ultrasonic dissolution；Then glycerol, the rilanit special, poly- second two of formula ratio is added
Pure and mild disodium ethylene diamine tetraacetate, stirs evenly, and adds water to 1000mL, filters through 0.45um sterilised membrane filter to get hydrochloric acid Lome
Husky star auristilla.
Embodiment 4
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 2.8g, glycerol 50g,
Peg40 rilanit special 13g, polyethylene glycol 400 25g, disodium ethylene diamine tetraacetate 1.0g.
The preparation method of lomefloxacin hydrochloride auristilla as described above, comprising the following steps: by the hydrochloric acid Lip river of formula ratio
U.S. sand star is added in suitable quantity of water, is heated to 42 DEG C, ultrasonic dissolution；Then glycerol, the rilanit special, poly- second two of formula ratio is added
Pure and mild disodium ethylene diamine tetraacetate, stirs evenly, and adds water to 1000mL, filters through 0.45um sterilised membrane filter to get hydrochloric acid Lome
Husky star auristilla.
Embodiment 5
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 3.2g, glycerol 45g,
Peg40 rilanit special 18g, polyethylene glycol 400 17g, disodium ethylene diamine tetraacetate 1.2g.
The preparation method of lomefloxacin hydrochloride auristilla as described above, comprising the following steps: by the hydrochloric acid Lip river of formula ratio
U.S. sand star is added in suitable quantity of water, is heated to 40 DEG C, ultrasonic dissolution；Then glycerol, the rilanit special, poly- second two of formula ratio is added
Pure and mild disodium ethylene diamine tetraacetate, stirs evenly, and adds water to 1000mL, filters through 0.45um sterilised membrane filter to get hydrochloric acid Lome
Husky star auristilla.
Embodiment 6
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 3g, glycerol 80g, peg40
Rilanit special 13g, polyethylene glycol 400 19g, disodium ethylene diamine tetraacetate 1.4g.
The preparation method of lomefloxacin hydrochloride auristilla as described above, comprising the following steps: by the hydrochloric acid Lip river of formula ratio
U.S. sand star is added in suitable quantity of water, is heated to 45 DEG C, ultrasonic dissolution；Then glycerol, the rilanit special, poly- second two of formula ratio is added
Pure and mild disodium ethylene diamine tetraacetate, stirs evenly, and adds water to 1000mL, filters through 0.45um sterilised membrane filter to get hydrochloric acid Lome
Husky star auristilla.
Embodiment 7
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 3g, glycerol 65g, peg40
Rilanit special 15g, polyethylene glycol 400 24g, disodium ethylene diamine tetraacetate 1g.
The preparation method of lomefloxacin hydrochloride auristilla as described above, comprising the following steps: by the hydrochloric acid Lip river of formula ratio
U.S. sand star is added in suitable quantity of water, is heated to 45 DEG C, ultrasonic dissolution；Then glycerol, the rilanit special, poly- second two of formula ratio is added
Pure and mild disodium ethylene diamine tetraacetate, stirs evenly, and adds water to 1000mL, filters through 0.45um sterilised membrane filter to get hydrochloric acid Lome
Husky star auristilla.
Embodiment 8
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 2.6g, glycerol 40g,
Peg40 rilanit special 13g, polyethylene glycol 400 19g, disodium ethylene diamine tetraacetate 0.7g.
The preparation method of lomefloxacin hydrochloride auristilla as described above, comprising the following steps: by the hydrochloric acid Lip river of formula ratio
U.S. sand star is added in suitable quantity of water, is heated to 45 DEG C, ultrasonic dissolution；Then glycerol, the rilanit special, poly- second two of formula ratio is added
Pure and mild disodium ethylene diamine tetraacetate, stirs evenly, and adds water to 1000mL, filters through 0.45um sterilised membrane filter to get hydrochloric acid Lome
Husky star auristilla.
Embodiment 9
A kind of lomefloxacin hydrochloride auristilla contains in every 1000mL auristilla: lomefloxacin hydrochloride 3g, glycerol 60g, peg40
Rilanit special 16g, polyethylene glycol 400 19g, disodium ethylene diamine tetraacetate 1.3g.
The preparation method of lomefloxacin hydrochloride auristilla as described above, comprising the following steps: by the hydrochloric acid Lip river of formula ratio
U.S. sand star is added in suitable quantity of water, is heated to 45 DEG C, ultrasonic dissolution；Then glycerol, the rilanit special, poly- second two of formula ratio is added
Pure and mild disodium ethylene diamine tetraacetate, stirs evenly, and adds water to 1000mL, filters through 0.45um sterilised membrane filter to get hydrochloric acid Lome
Husky star auristilla.
Test example
1, study on the stability
The lomefloxacin hydrochloride auristilla that Example 2 is prepared, be respectively placed in 5 DEG C 25 DEG C, under 35 DEG C of environment to outside it
Sight, pH value, content are observed, and are as a result had no significant change.
, pharmacodynamic test
100 patients for being diagnosed as otitis media purulenta chronica are taken, treatment group and control group are randomly divided into.Treatment group 50,
Male 25, female 25；Average age (42.6 ± 17.3) year, a month of average course of disease (9.85 ± 5.27).Control group 50, male 24
Example, female 26；Average age (46.1 ± 15.5) year, a month of average course of disease (10.34 ± 5.46)；Two groups of genders, age, courses of disease
It is statistically analyzed and does not have significant difference.
Diagnostic criteria: it is drafted according to " practical Otolaryngology " and " Otorhinolaryngology of TCM ": 1, intermittent or hold
Continuous property purulent ear, fester are mucus or glutinous purulence, and odorless, Se Bai or yellow, amount is more or few；2, eardrum is shown in toposcopy
Tense part of tympanic membrane has central perforation not of uniform size, tympanic mucosa hyperemia, oedema；Acoustic trauma is generally conduction deafness；X-ray or
CT shows that mastoid air cell is reduced, and density increases.
Two groups of case local treatments are identical.Ear canal is first cleaned with 3% hydrogen peroxide, fester is removed, suffers from ear and instill liquid medicine upward,
Treatment group instills the auristilla that the embodiment of the present invention 2 is prepared, and each 6-10 drop, it is husky that control group instills commercially available hydrochloric acid Lome
Star auristilla, each 6-10 drop；Two groups of oral Cefradine Capsules during treatment, each 0.5g, 4 times/d, the course for the treatment of 2 weeks.System
Counting curative effect, (criterion of therapeutical effect: cure: purulent ear stops, and checks that tympanum is done clean, mucous membrane is without congested or oedema.It is effective: stream in ear
Purulence substantially reduces, and inspection is shown in that tympanum without fester but humidity, or has a little secretion, mucous membrane Mild edema or hyperemia.It is invalid: ear
It inside suppurates without changing or increasing or slightly show reduction, looks into and see still there is more secretion in tympanum, mucous hyperemia, oedema), see simultaneously
Examining patient has (otalgia) without side-effects, the results are shown in Table 1.
Claims (5)
1. a kind of lomefloxacin hydrochloride auristilla, it is characterised in that contain in every 1000mL auristilla: lomefloxacin hydrochloride 2.5-
3.5g, glycerol 40-80g, rilanit special 12-18g, polyethylene glycol 15-25g, disodium ethylene diamine tetraacetate 0.6-1.4g.
2. lomefloxacin hydrochloride auristilla as described in claim 1, it is characterised in that contain in every 1000mL auristilla: hydrochloric acid
Lomefloxacin 3g, glycerol 60g, rilanit special 15g, polyethylene glycol 20g, disodium ethylene diamine tetraacetate 1g.
3. such as the described in any item lomefloxacin hydrochloride auristillas of claim 1-2, it is characterised in that the rilanit special is
Peg40 rilanit special.
4. such as the described in any item lomefloxacin hydrochloride auristillas of claim 1-2, it is characterised in that the polyethylene glycol is poly-
Ethylene glycol 400.
5. the preparation method of lomefloxacin hydrochloride auristilla according to any one of claims 1-4, it is characterised in that including with
Lower step: the lomefloxacin hydrochloride of formula ratio is added in suitable quantity of water, is heated to 40-50 DEG C, ultrasonic dissolution；Then formula is added
Glycerol, rilanit special, polyethylene glycol and the disodium ethylene diamine tetraacetate of amount, stir evenly, add water to 1000mL, through sterile filter
Film filters to get lomefloxacin hydrochloride auristilla.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811344857.XA CN109260152A (en) | 2018-11-13 | 2018-11-13 | A kind of lomefloxacin hydrochloride auristilla |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811344857.XA CN109260152A (en) | 2018-11-13 | 2018-11-13 | A kind of lomefloxacin hydrochloride auristilla |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109260152A true CN109260152A (en) | 2019-01-25 |
Family
ID=65193481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811344857.XA Pending CN109260152A (en) | 2018-11-13 | 2018-11-13 | A kind of lomefloxacin hydrochloride auristilla |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109260152A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999063968A1 (en) * | 1998-06-10 | 1999-12-16 | Wakamoto Pharmaceutical Co., Ltd. | Aqueous preparations containing hardly soluble drug |
| WO2002005850A2 (en) * | 2000-07-19 | 2002-01-24 | Pitmy International N.V. | Enhancement of the action of anti-infective agents |
| CN1446092A (en) * | 2000-08-08 | 2003-10-01 | 若素制药株式会社 | Aqueous pharmaceutical compositions |
| CN1662228A (en) * | 2002-05-23 | 2005-08-31 | Umd公司 | Compositions and method for transmucosal drug delivery and cryoprotection |
| CN102085203A (en) * | 2009-12-02 | 2011-06-08 | 沈阳兴齐制药有限公司 | Ophthalmic preparation of levofloxacin and prednisolone acetate and preparation method thereof |
| CN102811741A (en) * | 2010-03-01 | 2012-12-05 | 萨尔瓦特实验室股份有限公司 | Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation |
| CN107970244A (en) * | 2016-10-21 | 2018-05-01 | 武汉武药科技有限公司 | A kind of composition containing Ciprofloxacin and dexamethasone and preparation method thereof |
-
2018
- 2018-11-13 CN CN201811344857.XA patent/CN109260152A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999063968A1 (en) * | 1998-06-10 | 1999-12-16 | Wakamoto Pharmaceutical Co., Ltd. | Aqueous preparations containing hardly soluble drug |
| WO2002005850A2 (en) * | 2000-07-19 | 2002-01-24 | Pitmy International N.V. | Enhancement of the action of anti-infective agents |
| CN1446092A (en) * | 2000-08-08 | 2003-10-01 | 若素制药株式会社 | Aqueous pharmaceutical compositions |
| CN1662228A (en) * | 2002-05-23 | 2005-08-31 | Umd公司 | Compositions and method for transmucosal drug delivery and cryoprotection |
| CN102085203A (en) * | 2009-12-02 | 2011-06-08 | 沈阳兴齐制药有限公司 | Ophthalmic preparation of levofloxacin and prednisolone acetate and preparation method thereof |
| CN102811741A (en) * | 2010-03-01 | 2012-12-05 | 萨尔瓦特实验室股份有限公司 | Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation |
| CN107970244A (en) * | 2016-10-21 | 2018-05-01 | 武汉武药科技有限公司 | A kind of composition containing Ciprofloxacin and dexamethasone and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 孟胜男，胡容峰主编: "《药剂学》", 31 January 2016, 中国医药科技出版社 * |
| 杨进，陈建: "用正交试验法研制盐酸洛美沙星滴耳剂", 《中国药学杂志》 * |
| 温秋菊: "盐酸洛美沙星滴耳液的制备工艺研究", 《中国现代药物应用》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2295346C2 (en) | Method for treating middle ear infection cases | |
| Ramirez-R | Pulmonary alveolar proteinosis: treatment by massive bronchopulmonary lavage | |
| CN102079794B (en) | Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations | |
| Furst et al. | A rare complication of tooth abscess-Ludwig's angina and mediastinitis | |
| COser et al. | Malignant external otitis in infants | |
| CN109260152A (en) | A kind of lomefloxacin hydrochloride auristilla | |
| CA2993012C (en) | Topical formulations and treatments | |
| CN103751508B (en) | A kind of medicine for peri-operation period mouth care and preparation method thereof | |
| US8343464B2 (en) | Composition and method for treating eustachian tube dysfunction | |
| US8940319B2 (en) | Formulations, devices and methods for treating and preventing mucositis | |
| Grewal et al. | Tuberculous otitis media presenting as complications: report of 18 cases | |
| Ruddy et al. | Optimum management of the discharging ear | |
| CN103845496B (en) | A kind of application of Chinese medicine composition in the drug for preparing treatment tympanitis | |
| Flexner et al. | Contamination of the Fly with Poliomyelitis Virus: Tenth Note | |
| Spelman et al. | Metronidazole in the treatment of anginose infectious mononucleosis | |
| Gupta et al. | To study the role of antibiotic+ steroid irrigation of the middle ear in active chronic otitis media with small perforation and pulsatile discharge. | |
| RU59407U1 (en) | DEVICE FOR TYMPANO-ENDOSCOPY, DIAGNOSTICS AND TREATMENT OF MIDDLE EAR DISEASES IN CONTROLLED BAR | |
| JPH11180863A (en) | Medicine for treating meniere's disease | |
| Biedlingmaier | Two ear problems you may not need to refer: otitis externa and bullous myringitis | |
| RU2087166C1 (en) | Method for treating adenoiditis in children | |
| GEWANTER | Conservative treatment of sinusitis in children | |
| US11602541B2 (en) | Nasal spray composition | |
| Hara et al. | XCII Tuberculosis of the Maxillary Sinus: Report of a Case Treated with Streptomycin | |
| RU2161023C2 (en) | Method for performing continuous controlled introduction of drugs into the tenon' space | |
| CN105944076A (en) | Auristilla used for treating chronic suppurative otitis media |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190125 |